18:19 , May 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Patient sample and cell culture studies identified three broadly neutralizing antibodies (bNAbs) against HIV gp120 that could help treat the infection. Screening of neutralizing antibodies against HIV gp120 isolated from a patient with natural...
18:33 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Patient sample and cell culture studies identified a neutralizing antibody against HIV gp120 that could help treat HIV/AIDS. Screening of peripheral blood B cells from a patient followed by testing of antibody...
04:48 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

ViiV's HIV candidate fostemsavir meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) (formerly BMS-663068) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir...
23:27 , Oct 27, 2017 |  BC Extra  |  Clinical News

ViiV's HIV candidate meets in Phase III

ViiV Healthcare Ltd. (Brentford, U.K.) said oral fostemsavir (GSK3684934) met the primary endpoint in the Phase III BRIGHTE trial to treat heavily treatment-experienced patients with HIV-1 infection. In the trial's randomized cohort, fostemsavir led to...
00:01 , Sep 21, 2017 |  BC Extra  |  Preclinical News

NIAID, Sanofi develop trispecific bNAb for HIV

In a paper published in Science, researchers at NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and Sanofi (Euronext:SAN; NYSE:SNY) identified a trispecific broadly neutralizing antibody (bNAb) which conferred 100% protection against simian HIV...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five disease-associated...
01:05 , Feb 16, 2017 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
14:12 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Patient sample and cell culture studies identified a broadly neutralizing antibody (bnAb) against HIV gp120 that could help treat HIV infection. Screening of peripheral blood memory B cells from a patient with broad-spectrum HIV-neutralizing...
08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Methyltransferase like 3 (METTL3); METTL14

Infectious disease INDICATION: HIV / AIDs Cell culture studies suggest inhibiting METTL3 or METTL14 could help treat HIV / AIDS. In HIV-infected human CD4+ T cells, shRNA targeting METTL3 or METTL14 decreased levels of HIV gp120 and...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Clinical News

DS003: Phase I started

IPM began the double-blind, placebo-controlled, Belgian Phase I IPM 042 trial to evaluate single 1, 3 and 10 mg DS003 vaginal tablets in about 36 healthy female volunteers. The non-profit IPM has a royalty-free license...